Absci (ABSI) & The Competition Head to Head Comparison

Absci (NASDAQ:ABSIGet Rating) is one of 39 public companies in the “Commercial physical research” industry, but how does it contrast to its competitors? We will compare Absci to similar businesses based on the strength of its valuation, institutional ownership, analyst recommendations, dividends, risk, earnings and profitability.

Valuation & Earnings

This table compares Absci and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Absci $4.78 million -$100.96 million -1.05
Absci Competitors $2.80 billion $101.15 million 12.14

Absci’s competitors have higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

40.0% of Absci shares are held by institutional investors. Comparatively, 59.5% of shares of all “Commercial physical research” companies are held by institutional investors. 11.4% of shares of all “Commercial physical research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Absci and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Absci -2,633.14% -36.19% -22.99%
Absci Competitors -260.35% -8.17% -2.92%

Analyst Ratings

This is a summary of current ratings and recommmendations for Absci and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Absci 1 3 3 0 2.29
Absci Competitors 105 763 1300 30 2.57

Absci currently has a consensus target price of $24.00, indicating a potential upside of 585.71%. As a group, “Commercial physical research” companies have a potential upside of 48.09%. Given Absci’s higher possible upside, equities research analysts plainly believe Absci is more favorable than its competitors.

Summary

Absci competitors beat Absci on 11 of the 12 factors compared.

Absci Company Profile (Get Rating)

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.